DOI: http://dx.doi.org/10.18203/2349-2902.isj20212280

Prevalence of GATA-3 in invasive breast cancer and its significance in predicting response to neoadjuvant chemotherapy: a tertiary center experience

Anjali Singh, Amit Karnik, Akshay Anand

Abstract


Background: GATA-3 expression was shown to be an independent predictor of overall and disease-free survival in some studies, whereas others showed no difference. We prospectively studied GATA-3 expression in index breast cancer patients and co-related with other immunohistochemical (IHC) markers along with response evaluation in IIIB onwards receiving neoadjuvant chemotherapy. Objective was to determine the expression of GATA-3 in Indian breast cancer tissue specimens and correlating GATA-3 expression with existing clinicopathological, radiological and immunohistochemical markers of breast cancer as well as with clinical response in breast cancer patients receiving neoadjuvant chemotherapy.

Methods: It was a prospective study that was conducted from November 2016 to October 2017. GATA-3 expression in carci-noma breast tissue obtained by tru-cut biopsy was studied by IHC.

Results: The distribution of GATA-3 receptor positivity with age showed higher positivity (p=0.79) with the older age group. The distribution of biological receptors in breast cancer patients had shown the highest presence of GATA-3 (87.5%) followed by HER2/neu (62.5%), ER (60%) and PR (50%). GATA-3 receptor positivity showed maximum positivity with luminal A subtype (50 and 9.11=59.1%) followed by HER2/neu enriched subtype (48.9%). Triple-negative breast cancer patients showed 48% positivity for the GATA-3 receptor. GATA-3 receptor expression was more in the locally advanced stage of breast cancer as compared to the early stage (p=0.02). GATA-3 positive patients showed partial response to chemotherapy (75.8%).

Conclusions: There is a raised possibility that GATA-3 or its downstream genes could be used in the management of luminal breast cancer.


Keywords


GATA-3, Breast cancer, Immunohistochemical markers, Clinical response

Full Text:

PDF

References


Sundararaman T, Gupta G. Indian approaches to retaining skilled health workers in rural areas. Bull World Health Organ. 2011;89:73-7.

Swaminathan R, Selvakumaran R, Vinodha J, Ferlay J, Sauvaget C, Esmy PO, et al. Education and cancer incidence in a rural population in south India. Cancer Epidemiol. 2009;33:89-93.

Reddy N, Ninan T, Tabar L, Bevers T. The results of a breast cancer screening camp at a district level in rural India. Asian Pac J Cancer Prev. 2012;13:6067-72.

Patient RK, McGhee JD. The GATA family (vertebrates and invertebrates). Curr Opin Genet Dev. 2002;12:416-22.

Lowry JA, Atchley WR. Molecular evolution of the GATA family of transcription factors: conservation within the DNA-binding domain. J Mol Evol. 2000;50:103-15.

Kouros-Mehr H, Bechis SK, Slorach EM. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell. 2008;13:141-52.

Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010;23:654-61.

Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA-3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138:57-64.

Miettinen M, McCue PA, Sarlomo-Rikala M. GATA-3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38:13-22.

Higgins JPT, Kaygusuz G, Wang L. Placental S100 (S100P) and GATA-3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-80.

Ciocca V, Daskalakis C, Ciocca RM, Ruiz-Orrico A, Palazzo JP. The significance of GATA-3 expression in breast cancer: a 10-year followup study. Hum Pathol. 2009;40:489-95.

Gonzalez RS, Wang J, Kraus T, Sullivan H, Adams AL, Cohen C. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Hum pathol. 2012.

Chen Y, Chen C, Yang B. Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. Cancer Lett. 2011;302:63-8.

Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D. Identification of GATA-3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005;65:11259-64.

Tominaga N, Naoi Y, Shimazu K. Clinicopathological analysis of GATA-3-positive breast cancers with special reference to response to neoadjuvant chemotherapy. Ann Oncol. 2012.

Yoon NK, Maresh EL, Shen D. Higher levels of GATA-3 predict better survival in women with breast cancer. Hum pathol. 2010;41:1794-801.

Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev. 2008;17:365-73.

Gonzalez RS, Wang J, Kraus T, Sullivan H, Adams AL, Cohen C. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Hum pathol. 2012.